Claims
- 1. A method of treating Alzheimer's disease in a human which comprises administering to said human an effective amount of a non-steroidal COX-2 inhibitor, wherein said non-steroidal COX-2 inhibitor will bind at least 100 times as well to COX-2 as to COX-1.
- 2. A method according to claim 1 wherein the administration is oral administration.
- 3. A method according to claim 2 wherein the non-steroidal COX-2 inhibitor is within a tablet or capsule.
- 4. A method according to claim 3 wherein said COX-2 inhibitor is selected from:
(a) 3-(4-(Aminosulfonyl)phenyl)-2-(4-fluorophenyl)-5-(2-hydroxy-2-propyl)thiophene, (b) 3-(4-(Aminosulfonyl)phenyl)-2-(4-fluorophenyl)thiophene, (c) 3-(4-(Aminosulfonyl)phenyl)-2-(4-fluorophenyl)-5-(2-propyl)thiophene, (d) 3-(4-(Aminosulfonyl)phenyl)-2-cyclohexylthiophene, (e) 5-(4-Carboxyphenyl)-4-(4-(methylsulfonyl)phenyl) thiophene-2-carboxylic acid, (f) 4-(4-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)thiazole, (g) 2-(4-Fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten-1-one (h) 4-(4-(Methylsulfonyl)phenyl)-5-(4-fluorophenyl)-isothiazole, (i) 3-(4-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone, (j) 3-(4-Fluorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)-furanone, (k) 3-(4-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl) furan, (l) 5,5-Dimethyl-3-(4-fluorophenyl)-4-(4-methylsulfonyl) phenyl)-2-(5H)-furanone, (m) 2-(4-(Aminosulfonyl)phenyl)-3-(4-fluorophenyl) thiophene, (n) 3-(4-(Trifluoroacetylaminosulfonyl)phenyl)-2-(4-fluorophenyl)thiophene, (o) 3-(3- Fuorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone, (p) 5,5-Dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl) phenyl)-2- (5H)-furanone, (q) 5,5-Dimethyl-3-(3-chlorophenyl)-4-(4-methylsulfonyl) phenyl)-2-(5H)-furanone, (r) 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone, (s) 3-(3,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; (t) 5,5-Dimethyl-3-(3,4-difluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone, (u) 5,5-Dimethyl-3-(3,4-dichlorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone, (v) 5,5-Dimethyl-3-(4-chlorophenyl)-4-(4-methylsufonyl)phenyl)-2-(5H) -furanone, (w) 3-(2-Naphthyl)-4-(4-(methylsulfonylphenyl)-furanone, (x) 5,5-Dimethyl-3-(2-naphthyl)-4-(4-(methylsulfonyl) phenyl)-2-(5H)-furanone, and (y) 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone.
- 5. A method of treating dementia associated with Alzheimer's disease in a human which comprises administering to said human an effective amount of a non-steroidal COX-2 inhibitor, wherein said non-steroidal COX-2 inhibitor will bind at least 100 times as well to COX-2 as to COX-1.
- 6. A method according to claim 5 wherein the administration is oral administration.
- 7. A method according to claim 6 wherein the non-steroidal COX-2 inhibitor is within a tablet or capsule.
- 8. A method according to claim 7 wherein the COX-2 inhibitor is selected from:
(a) 3-(4-(Aminosulfonyl)phenyl)-2-(4-fluorophenyl)-5-(2-hydroxy-2-propyl)thiophene, (b) 3-(4-(Aminosulfonyl)phenyl)-2-(4-fluorophenyl)thiophene, (c) 3-(4-(Aminosulfonyl)phenyl)-2-(4-fluorophenyl)-5-(2-propyl)thiophene, (d) 3-(4-(Aminosulfonyl)phenyl)-2-cyclohexylthiophene, (e) 5-(4-Carboxyphenyl)-4-(4-(methylsulfonyl)phenyl) thiophene-2-carboxylic acid, (f) 4-(4-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)thiazole, (g) 2-(4-Fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten-1-one (h) 4-(4-(Methylsulfonyl)phenyl)-5-(4-fluorophenyl)-sothiazole, (i) 3-(4-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone, (j) 3-(4-Fluorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)-furanone, (k) 3-(4-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl) furan, (l) 5,5-Dimethyl-3-(4-fluorophenyl)-4-(4-methylsulfonyl) phenyl)-2-(5H)-furanone, (m) 2-(4-(Arninosulfonyl)phenyl)-3-(4-fluorophenyl) thiophene, (n) 3-(4-(Trifluoroacetylaminosulfonyl)phenyl)-2-(4-fluorophenyl)thiophene, (o) 3-(3-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone, (p) 5,5-Dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl) phenyl)-2-(5H)-furanone, (q) 5,5-Dimethyl-3-(3-chlorophenyl)-4-(4-methylsulfonyl) phenyl)-2-(5H)-furanone, (r) 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone, (s) 3-(3,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone, (t) 5,5-Dimethyl-3-(3,4-difluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone, (u) 5,5-Dimethyl-3-(3,4-dichlorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone, (v) 5,5-Dimethyl-3-(4-chlorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone, (w) 3-(2-Naphyhyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone, (x) 5,5-Dimethyl-3-(2-naphyhyl)-4-(4-(methylsulfonyl) phenyl)-2-(5H)-furanone, and (y) 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone.
- 9. A method according to claim 1 wherein the COX-2 inhibitor is of formula I
224
Priority Claims (1)
Number |
Date |
Country |
Kind |
9420616.6 |
Oct 1994 |
GB |
|
RELATED US APPLICATION DATA
[0001] This is a continuation in part of U.S. Ser. No. 08/539,930 filed Oct. 6, 1995 which is a continuation in part of co-pending U.S. Ser. No. 08/461,783 filed Jun. 5, 1995 which is a continuation-in-part of 08/179,467 filed Jan. 10, 1994 which is a continuation-in-part of U.S. Ser. No. 08/082,196 filed Jun. 24, 1993.
Continuations (2)
|
Number |
Date |
Country |
Parent |
09552974 |
Apr 2000 |
US |
Child |
09796211 |
Feb 2001 |
US |
Parent |
09161516 |
Sep 1998 |
US |
Child |
09552974 |
Apr 2000 |
US |
Continuation in Parts (4)
|
Number |
Date |
Country |
Parent |
08539930 |
Oct 1995 |
US |
Child |
09161516 |
Sep 1998 |
US |
Parent |
08461783 |
Jun 1995 |
US |
Child |
08539930 |
Oct 1995 |
US |
Parent |
08179467 |
Jan 1994 |
US |
Child |
08461783 |
Jun 1995 |
US |
Parent |
08082196 |
Jun 1993 |
US |
Child |
08179467 |
Jan 1994 |
US |